Outlook Therapeutics (OTLK) announced that the U.S. Food and Drug Administration, FDA, has acknowledged receipt of the resubmission of the Biologics License Application, BLA, for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration. The FDA has advised that it considers the BLA resubmission a complete, Class 1 response to the August 27, 2025 action letter, which results in a 60 day review period from the date of resubmission. As a result, the FDA has set a Prescription Drug User Fee Act, PDUFA, goal date of December 31, 2025. ONS-5010, if approved, will be branded as LYTENAVA for the treatment of wet AMD.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics Resubmits Biologics License Application
- Outlook Therapeutics resubmits BLA for ONS-5010
- Outlook Therapeutics: Hold Rating Amid Uncertainties in BLA Resubmission and Market Challenges
- Outlook Therapeutics Completes FDA Meeting on ONS-5010
- Outlook Therapeutics says plans to resubmit BLA before end of CY25